CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Diagnosis and management of pituitary tumours in the elderly: A review based on personal experience and evidence of literature
Authors
Esposito V.
Fratticci A.
+4 more
Jaffrain-Rea M. -L.
Minniti G.
Piccirilli M.
Santoro A.
Publication date
1 January 2005
Publisher
'Bioscientifica'
Doi
Cite
Abstract
6nononeAn increasing proportion of pituitary adenomas are recognized in the elderly, raising the question of their optimal diagnosis and management. Age-related endocrine changes and associated diseases may significantly modify the clinical presentation and hormonal evaluation of these patients. About 80% of pituitary adenomas in this age group are non-secreting, requiring careful differential diagnosis with non-adenomatous sellar lesions. In this group, visual deterioration and hypopituitarism remain the leading symptoms. Recognized secreting tumours are mainly GH-secreting, most of them intrasellar, followed by prolactinomas, which present as clinically non-secreting and are usually invasive. Cushing's disease appears as a very rare eventuality in the elderly. Optimal therapeutic management should aim to control the disease while preserving or improving patient's quality of life. Transsphenoidal surgery has proved to be an efficient and well-tolerated option for non-secreting adenomas with visual defects and intrasellar GH-secreting adenomas, being able to improve metabolic and cardiovascular complications of acromegaly even in this age group. In contrast, dopamine-agonist drugs can be proposed as a primary therapy for prolactinomas even in the presence of severe neurological complications. Because the use of radiotherapy is hampered by its delay of action and potential neurological side effects, its indications should be better defined in this age group. The clinical importance of hypopituitarism should not be underestimated, and thyroid- and adrenal-replacement therapy are mandatory in the presence of documented hormone deficiency, carefully avoiding overtreatment in order to limit possible side effects on the cardiovascular system and bone mineralization. Indications for GH- and sex steroid-replacement therapy still await age-specific guidelines. © 2005 Society of the European Journal of Endocrinology.noneMinniti G.; Esposito V.; Piccirilli M.; Fratticci A.; Santoro A.; Jaffrain-Rea M.-L.Minniti, G.; Esposito, V.; Piccirilli, M.; Fratticci, A.; Santoro, A.; Jaffrain-Rea, M. -L
Similar works
Full text
Available Versions
Archivio della Ricerca - Università degli Studi di Siena
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:usiena-air.unisi.it:11365/...
Last time updated on 08/08/2022
Archivio della Ricerca - Università degli Studi di Siena
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:usiena-air.unisi.it:11365/...
Last time updated on 08/08/2022